(Paris) The French-Canadian pharmaceutical company Angany has started a first clinical trial aimed at testing a vaccine in humans to treat cat hair allergy, according to a press release received on Monday.
The vaccine candidate, called ANG-101, is based on the development of a “bioparticle that mimics the shape and size of a virus and whose surface is covered with thousands of copies of the main cat allergen, the Fel d1 protein,” the company explains.
The first patients were recruited at the Royal Brompton Hospital in London to begin clinical trials.
This treatment, previously tested on animals, triggered “a very strong production of antibodies capable of blocking the allergic reaction,” Angany co-founder Loïc Faye told AFP.
The current treatment of allergies consists of injecting increasing doses of allergen extracts: this is desensitization, a lengthy process and not always effective. Antihistamines are also used to relieve allergy symptoms.
“ANG-101 is the first in a portfolio of vaccines in development targeting severe allergies in humans and pets,” emphasizes Louis-Philippe Vézina, President and CEO of Angany, in the press release.
The technology was developed in France, in Val-de-Reuil, by the French start-up Angany Genetics, which was founded in 2010 and became Angany after transitioning to Canadian ownership in 2017.
Extreme problem solver. Professional web practitioner. Devoted pop culture enthusiast. Evil tv fan.
;Composite=(type=URL,url=https://images.radio-canada.ca/v1/assets/elements/16x9/outdated-content-2021.png),gravity=SouthEast,placement=Over,location=(0,0),scale=1)
